Sponsor or institution
Clinical trials and research at Rigel Pharmaceuticals
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Rigel Pharmaceuticals that are recruiting, at sites in 8 countries (most in United States (3), Australia (1), Canada (1)). By phase: Phase 4 (2), Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 8Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors | Phase 4 | Logroño, La Rioja and 1 other locations | Recruiting | Jul 15, 2026 |
| Olutasidenib drug interaction testing for IDH1‑mutant cancers | Phase 4 | Orange, California and 1 other locations | Recruiting | Mar 20, 2026 |
| Treatment of high-grade glioma in young patients using olutasidenib and temozolomide | Phase 2 | Aurora, Colorado and 19 other locations | Recruiting | Dec 8, 2023 |
| Treatment for patients with lower-risk myelodysplastic syndromes using R289 | Phase 1/2 | Los Angeles, California and 12 other locations | Recruiting | Apr 4, 2022 |
All recruiting trials (4)
-
Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors
This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.
-
Olutasidenib drug interaction testing for IDH1‑mutant cancers
This trial tests whether the cancer drug olutasidenib changes how the body processes other medicines in adults with IDH1‑mutation positive cancers.
-
Treatment of high-grade glioma in young patients using olutasidenib and temozolomide
This study is testing if a new combination of olutasidenib and temozolomide can help young patients with high-grade gliomas that have a specific mutation feel better after their radiotherapy.
-
Treatment for patients with lower-risk myelodysplastic syndromes using R289
This study is testing a new treatment called R289 to see if it can help people with lower-risk myelodysplastic syndromes who haven't responded well to other therapies.
Quick answers
How many clinical trials run by Rigel Pharmaceuticals are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 8 countries. The most sites are in United States (3 trials), Australia (1 trial), Canada (1 trial), Germany (1 trial), Netherlands (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 2, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.